Related Experiment Videos
Pharmacokinetics and safety of cefamandole in newborn infants
Insights
Cefamandole effectively treated Staphylococcus aureus skin infections in newborns. This new cephalosporin antibiotic showed higher serum levels and longer half-life in infants compared to older patients.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Pustular skin infections in newborns caused by Staphylococcus aureus pose a significant clinical challenge.
- Parenteral cephalosporins are crucial for treating bacterial infections, but their use in neonates requires careful evaluation.
- Limited data exists on the pharmacokinetics of newer cephalosporins, like cefamandole, in the neonatal population.
Purpose of the Study:
- To evaluate the efficacy and safety of cefamandole in treating neonatal skin infections.
- To assess the pharmacokinetic profile of cefamandole in newborn infants.
- To compare cefamandole's serum levels and half-life in neonates with data from older age groups.
Main Methods:
- A cohort of 23 newborn infants with Staphylococcus aureus pustular skin infections received cefamandole.
- Treatment duration averaged 7.5 days, administered via intravenous or intramuscular routes.
- Clinical improvement, adverse events (serum glutamic oxaloacetic transaminase, eosinophilia, renal function), and Coombs' test results were monitored.
Main Results:
- All 23 infants demonstrated clinical improvement following cefamandole treatment.
- Transient elevations in serum glutamic oxaloacetic transaminase and eosinophilia occurred in nine infants each.
- Cefamandole exhibited higher serum concentrations and a longer mean half-life in neonates compared to older individuals.
Conclusions:
- Cefamandole is an effective antibiotic for treating Staphylococcus aureus pustular skin infections in neonates.
- The safety profile was favorable, with no significant renal function abnormalities or positive Coombs' test results.
- Neonates demonstrate distinct pharmacokinetics for cefamandole, necessitating age-specific dosing considerations.
Abstract:
Cefamandole, a new parenteral cephalosporin antibiotic, was administered to 23 newborn infants with pustular skin infection due to Staphylococcus aureus for an average duration of 7.5 days. All the patients improved clinically. Elevation of serum glutamic oxaloacetic transaminase and eosinophilia were observed in nine infants each transiently during treatment. There were no abnormalities of renal functions and Coombs' test results remained negative. The levels of cefamandole in serum after either intravenous or intramuscular administration were higher and the mean life was longer than those previously reported in older infants, children, and adults.